V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 10448427 | 10071308 | 1.36 | 78 | null | 2018-02-16 | 2019-04-12 | AXITINIB | 02 | null | BLEOMYCIN | 100597119 |
| 10449361 | 10071309 | 1.83 | 87.4 | Palliative (P) | 2020-05-26 | 2020-05-26 | IGEV R | 02 | N | CYCLOPHOSPHAMIDE + DOXORUBICIN + VINCRISTINE | 101620296 |
| 10450664 | 10071312 | null | 48.7 | null | 2020-04-14 | 2020-04-20 | Oxaliplatin + Raltitrexed | 02 | null | CAPECITABINE + CARBOPLATIN + EPIRUBICIN | 100421788 |
| 10451466 | 10071313 | 1.84 | 96.1 | Curative (C) | 2018-07-06 | 2019-11-23 | Ipilimumab | 02 | N | TRASTUZUMAB EMTANSINE | 101657859 |
| 10451574 | 10071314 | 1.72 | 70.3 | Palliative (P) | 2019-12-06 | 2019-12-06 | Cyclophos + Dex + Lenalidomide | 02 | N | BCG | 101833820 |
| 10451624 | 10071315 | 1.72 | 81.1 | Palliative (P) | 2016-04-04 | 2020-02-20 | Liposomal Doxorubicin (Caelyx) | 02 | N | MITOMYCIN INTRAVESICULAR | 100630641 |
| 10451796 | 10071317 | null | null | Adjuvant (A) | 2019-11-15 | 2019-11-15 | null | 02 | N | MITOMYCIN | 100355081 |
| 10454229 | 10071319 | 1.54 | null | null | 2017-11-21 | 2017-11-29 | R GCVP | 02 | null | CAPECITABINE + STREPTOZOCIN | 101420082 |
| 10454721 | 10071320 | null | null | Curative (C) | null | 2022-03-09 | Erlotinib | 02 | N | CLADRIBINE + RITUXIMAB | 101295477 |
| 10455491 | 10071322 | 1.81 | 65.8 | Palliative (P) | null | 2018-12-24 | BENDAMUSTINE + THALIDOMIDE | 02 | N | DACARBAZINE | 100792335 |
| 10455599 | 10071323 | 1.77 | 89 | Palliative (P) | 2020-12-31 | 2021-01-06 | null | 02 | N | DOXORUBICIN EMBOLISATION | 101486861 |
| 10456315 | 10071324 | 1.69 | 75.2 | null | 2021-01-03 | 2021-01-03 | null | 02 | null | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 100751880 |
| 10457185 | 10071325 | null | null | null | 2018-04-01 | 2018-12-05 | EVEROLIMUS | 02 | null | BRENTUXIMAB | 101304930 |
| 10459636 | 10071328 | 1.66 | 60.9 | null | 2022-04-29 | 2022-05-04 | Inotuzumab Ozogamicin | 02 | null | AZACITIDINE + VENETOCLAX | 101531292 |
| 10460666 | 10071331 | 1.68 | 81.2 | null | 2022-02-17 | 2022-03-07 | null | 02 | null | FLUOROURACIL + IRINOTECAN + OXALIPLATIN | 101298396 |
| 10463139 | 10071334 | null | null | null | 2017-09-03 | 2018-02-28 | AZACITIDINE + VENETOCLAX | 02 | null | SOTORASIB | 100821151 |
| 10463388 | 10071336 | 1.67 | 69.05 | null | 2021-03-24 | 2021-03-24 | Irinotecan | 02 | null | BOSUTINIB | 100668308 |
| 10463797 | 10071337 | 1.81 | 79 | Disease modification (D) | 2017-07-15 | 2017-07-15 | Cytarabine High Dose | 02 | N | IRINOTECAN | 100361329 |
| 10464201 | 10071338 | 1.75 | 80 | Palliative (P) | 2020-05-20 | 2020-05-20 | Bevacizumab | 02 | N | FLUOROURACIL + MITOMYCIN | 100004424 |
| 10464960 | 10071339 | 1.81 | 95.2 | Curative (C) | 2022-02-07 | 2022-02-08 | Oxaliplatin + Modified de Gramont | 02 | N | ICON8B TRIAL | 101572022 |
| 10465735 | 10071340 | 1.62 | 0 | null | 2021-03-02 | 2021-03-25 | null | 02 | null | PEMETREXED | 101320526 |
| 10465757 | 10071341 | 1.63 | 0 | Neo-adjuvant (N) | 2021-04-08 | 2021-06-28 | Oxaliplatin + Raltitrexed | 02 | N | BEVACIZUMAB | 101283390 |
| 10466432 | 10071342 | 1.73 | 81.2 | null | 2017-05-06 | 2017-05-16 | OSIMERTINIB | 02 | N | VISMODEGIB | 101256506 |
| 10467214 | 10071345 | null | 55 | null | 2022-01-28 | 2022-02-21 | BEAM | 02 | null | EPIRUBICIN | 101200479 |
| 10467904 | 10071346 | 1.57 | 75.3 | null | 2019-08-15 | 2019-12-17 | Carboplatin + Pembrolizumab + Pemetrexed | 2 | null | CHLORAMBUCIL + RITUXIMAB | 101058072 |
| 10468857 | 10071347 | 1.64 | 66.7 | null | 2019-12-10 | 2020-02-03 | IRINOTECAN + MDG | 02 | null | SUNITINIB | 101815249 |
| 10468917 | 10071348 | 1.85 | 59.1 | null | null | 2020-11-10 | CHLVPP | 02 | N | EPIRUBICIN + ETOPOSIDE + IFOSFAMIDE | 101316497 |
| 10469699 | 10071349 | 1.84 | 105.9 | Palliative (P) | 2021-08-28 | 2021-08-30 | Methotrexate intrathecal | 02 | N | CYCLOPHOSPHAMIDE + ETOPOSIDE + RITUXIMAB + VINCRISTINE | 101325936 |
| 10471432 | 10071355 | 1.64 | 74.15 | null | 2019-11-03 | 2019-11-07 | OSIMERTINIB | 02 | N | OBINUTUZUMAB | 101558510 |
| 10472643 | 10071357 | 1.8 | 63.3 | Palliative (P) | 2020-11-28 | 2021-02-21 | Pemetrexed | 02 | N | CISPLATIN + CYTARABINE + ETOPOSIDE + RITUXIMAB | 100471881 |
| 10473818 | 10071360 | null | null | Curative (C) | 2018-09-06 | 2019-11-24 | VISMODEGIB | 01 | N | CTD | 101654071 |
| 10474622 | 10071361 | 1.78 | 99.1 | Curative (C) | 2017-05-21 | 2018-11-22 | Obinutuzumab +CVP | 02 | N | BENDAMUSTINE + OBINUTUZUMAB | 101012081 |
| 10476546 | 10071364 | 0 | 108 | null | 2017-12-22 | 2017-12-25 | TRANSPLANT CYCLOPHOSPHAMIDE + FLUDARABINE (+/- TBI) | 02 | null | BEVACIZUMAB + CARBO + PACLITAXEL | 101634362 |
| 10476699 | 10071365 | 1.71 | 87 | Palliative (P) | 2021-01-30 | 2021-04-05 | null | 02 | N | FLUOROURACIL + MITOMYCIN | 101630583 |
| 10477187 | 10071367 | null | null | null | 2017-07-03 | 2017-11-04 | Mitomycin Intravesical | 02 | null | CYTARABINE | 101650732 |
| 10477608 | 10071368 | 1.81 | 53.7 | null | 2019-12-21 | 2019-12-26 | null | null | null | BEVACIZUMAB | 100258500 |
| 10478176 | 10071370 | 1.67 | 68 | null | 2022-03-16 | 2022-05-12 | Cyclophosphamide + Docetaxel + Trastuzumab | 02 | null | VISMODEGIB | 100836889 |
| 10478706 | 10071371 | null | null | Palliative (P) | 2019-08-06 | 2019-10-27 | Alectinib | 02 | N | RALTITREXED | 100376229 |
| 10478853 | 10071372 | 1.55 | 71.3 | Palliative (P) | 2020-06-29 | 2020-07-06 | ECX | 02 | N | CARBOPLATIN + PEMBROLIZUMAB + PEMETREXED | 101425103 |
| 10479339 | 10071373 | 1.71 | 77.2 | null | 2018-12-13 | 2018-12-21 | PEMBROLIZUMAB + PEMETREXED | 02 | null | CVP R | 100786757 |
| 10479484 | 10071374 | 0 | null | null | null | 2022-03-21 | Trial Unspecified | 02 | null | CYTARABINE | 101195190 |
| 10480650 | 10071377 | 1.81 | 64 | null | 2021-03-01 | 2021-03-09 | Obinutuzumab + Venetoclax | 01 | null | TRABECTEDIN | 101161113 |
| 10025690 | 10071381 | 1.84 | 65.2 | Palliative (P) | 2021-01-20 | 2021-09-25 | null | 02 | N | RUCAPARIB | 100195169 |
| 10040757 | 10071382 | 0 | 69.5 | null | 2020-04-24 | 2020-04-29 | Ralitrexed | 02 | null | TRANSPLANT CARBOPLATIN + CYCLOPHOSPHAMIDE + ETOPOSIDE + PACLITAXEL | 101688093 |
| 10057843 | 10071383 | 1.5 | 66 | Palliative (P) | 2019-09-15 | 2020-08-08 | IDELALISIB | N | Y | ANAGRELIDE | 101687648 |
| 10100529 | 10071384 | 1.77 | 117 | null | null | 2022-05-02 | Cyclophosphamide + Dex + Rituximab | 02 | null | CISPLATIN + GEMCITABINE + RITUXIMAB | 101475996 |
| 10104573 | 10071385 | 0 | 64 | null | 2019-02-10 | 2019-02-21 | null | 02 | null | CAPECITABINE + CISPLATIN | 100510185 |
| 10115321 | 10071386 | 1.72 | 72.5 | null | 2021-12-14 | 2022-02-28 | Doxorubicin + Olaratumab | 01 | null | INTERFERON ALFA | 101842694 |
| 10133733 | 10071387 | 1.66 | 72.5 | null | 2020-01-06 | 2020-01-13 | BOSUTINIB | 02 | null | VINCRISTINE | 101578948 |
| 10137589 | 10071388 | 1.63 | 94.6 | Palliative (P) | 2020-07-04 | 2020-07-11 | FLAIR trial | N | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100966751 |